antiviral prophylaxis

Efficacy and Outcomes of Short-Course Perioperative Antiviral Prophylaxis in Hepatitis C Viremic Donor Kidney Transplantation

By MedXY 08/20/2026

A 7-day perioperative sofosbuvir/velpatasvir prophylaxis in HCV-positive donor to HCV-negative recipient kidney transplants demonstrated sustained virologic response in over 92% of cases, with favorable 1-year graft survival and function.

Gastroenterology news Oncology

Antiviral Prophylaxis Levels the Playing Field: Safe ICI Use in High-Viral Load HBV-HCC Patients

By MedXY 01/12/2026

A prospective study demonstrates that concurrent antiviral prophylaxis effectively mitigates HBV reactivation risk in HCC patients treated with PD-1/L1 inhibitors, regardless of baseline viral load, challenging traditional clinical trial exclusion criteria.

Infectious Diseases news Public Health

Daily High‑Dose Mosnodenvir Significantly Lowers DENV‑3 Viremia in a Human Challenge — Proof‑of‑Concept with Early Resistance Signals

By MedXY 11/27/2025

In a phase 2a human challenge, high‑dose daily mosnodenvir substantially reduced DENV‑3 RNA burden versus placebo without serious adverse events, but treatment‑associated NS4B viral mutations emerged, highlighting efficacy and resistance concerns that require larger field studies.